Stem Cell Therapeutics Corp. is a Canadian biotechnology company (TSX-V: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient’s own resident stem cells. The company’s programs aim to repair neurological function lost due to disease or injury.


Our lead program, NTx®-265, is a regimen of two approved and marketed drugs targeting the treatment of stroke. The therapy works by stimulating the growth and differentiation of new neurons to replace the brain cells that are lost or damaged by the stroke and importantly, to direct motor, visual and cognitive recovery after acute ischemic stroke. Our approach avoids surgical transplantation of stem cells; instead we use drugs to stimulate the body’s own existing adult stem cells.

OUR COMPANY

Learn about the people and principles that are driving our company towards success.

OUR TECHNOLOGY

Discover some of the exciting technologies that we are developing.

INVESTORS

Realize how we are dedicated to providing long-term shareholder value.

UPCOMING MILESTONES

Q1 10
Complete patient enrollment in modified REGENESIS Phase IIb acute ischemic stroke trial
Q2 10
Report Top-line modified REGENESIS Phase IIb stroke trial data
H1 10
Initiate and enrol patients in a Phase IIa clinical study for traumatic brain injury
H2 10
Initiate clinical Proof-of-Concept study for multiple sclerosis
H2 10
Complete preclinical study for hemorrhagic stroke
H2 10
Complete 'end of Phase II' meeting with the FDA prior to initiating the Phase III stroke trial
©2004 - 2010 Stem Cell Therapeutics - All rights reserved